What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GLP-1 receptor agonist (long-acting)
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating Liraglutide through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
Liraglutide is the original molecule that proved out the lipidation-based half-life-extension strategy that Semaglutide and Tirzepatide later refined and extended. Structurally it is a 31-residue GLP-1 receptor agonist carrying a single C16 palmitic-acid moiety attached to Lys26 through a glutamic-acid (gamma-Glu) spacer, plus an Arg-for-Lys swap at position 34 designed to block off-target lipidation in the synthesis step. The C16 fatty acid is the load-bearing modification: it drives reversible serum-albumin binding that pulls plasma half-life out of the minutes-scale window of native GLP-1 and up to roughly 13 hours, which supports once-daily subcutaneous dosing, the longer C18 and C20 successors push half-life into the weekly range, but Liraglutide stopped at C16 by design. The same API underpins two approved finished drugs: Victoza, with the original 2010 FDA approval for T2DM, and Saxenda, with the subsequent 2014 FDA approval for chronic weight management. Vialdyne releases Liraglutide acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The standard release packet covers RP-HPLC peak integration, ESI-MS at the lipidated 3751.20 g/mol average theoretical mass, Karl Fischer water, and counter-ion. LC-MS/MS sequence verification is the recommended add-on test at first-time pharmacy qualification: the 31-residue sequence with a lipidation modification places this molecule at the more demanding end of routine SPPS, and the diagnostic mass-spec check has to confirm the dominant species sits at the lipidated mass, not at the unmodified GLP-1 mass. Three standard strengths (5, 10, 30 mg) cover compounding-pharmacy dispensing workflows; sterile-filled presentations are scoped under change-control. For the wider pharmacology context across the GLP-1 family of approved and investigational agents, our companion [class comparison article](/insights/glp-1-class-comparison-tirzepatide-retatrutide-mazdutide-survodutide) walks the side-by-side.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for Liraglutide, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →Liraglutide
VD260428-LL129 · 99.65%
VerifiedRequest full COA →Liraglutide
VD260428-LL130 · 99.53%
VerifiedRequest full COA →Liraglutide
VD260428-LL128 · 99.56%
Regulatory note
Major regulators including the FDA, EMA, and others have approved finished Liraglutide drug products — Victoza for type 2 diabetes and Saxenda for chronic weight management. The active on its own, though, is absent from the 503A bulks list; whether compounding is permitted hinges on the destination market's regulatory posture and current shortage status, a determination buyers must verify at the time of dispense.
Selected literature
Frequently asked questions
The lipidated GLP-1 backbone ships lyophilised and stays sealed at -20 C, dry, until the compounding session, following a documented re-test schedule printed on the released-batch certificate. Because the defining feature is a gamma-Glu-palmitoyl chain at Lys26, handling should limit moisture exposure and repeated warming that could promote hydrolysis of the lipid or the peptide backbone. Reconstitute only at point of use, aliquot into single-use volumes at once, and treat freeze-thaw count as the dominant potency variable. Any documented cold-chain excursion in transit should prompt an incoming-inspection potency check before the lot enters production.
Mass-spec at the lipidated mass confirms the palmitoyl conjugation completed, but a pharmacy also wants the purity and net-peptide picture. Request RP-HPLC main-peak area with the related-substance profile, so incompletely lipidated or des-amino impurities are visible and quantified rather than merely excluded by the identity peak. Water content and counter-ion quantitation drive the net-peptide mass used to calculate a fill. If the active feeds a sterile injectable, extend the same lot to endotoxin and microbial-limits testing. Bundling these with the lipidated-mass confirmation gives receiving inspection a complete release record on one certificate.
Related peptides
